Handelsbanken Fonder AB Buys 35,343 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Share on StockTwits

Handelsbanken Fonder AB increased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 353.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,343 shares of the biopharmaceutical company’s stock after buying an additional 35,343 shares during the quarter. Handelsbanken Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $28,278,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Endurance Wealth Management Inc. boosted its position in Regeneron Pharmaceuticals by 56.3% in the second quarter. Endurance Wealth Management Inc. now owns 50 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 18 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its position in Regeneron Pharmaceuticals by 460.0% in the second quarter. San Francisco Sentry Investment Group CA now owns 56 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 46 shares during the last quarter. Kistler Tiffany Companies LLC boosted its position in Regeneron Pharmaceuticals by 51.3% in the second quarter. Kistler Tiffany Companies LLC now owns 59 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Farmers & Merchants Investments Inc. boosted its position in Regeneron Pharmaceuticals by 64.9% in the second quarter. Farmers & Merchants Investments Inc. now owns 61 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 24 shares during the last quarter. Finally, Citizens Financial Group Inc RI boosted its position in Regeneron Pharmaceuticals by 133.3% in the second quarter. Citizens Financial Group Inc RI now owns 63 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 36 shares during the last quarter. Institutional investors and hedge funds own 85.89% of the company’s stock.

A number of research analysts have recently commented on REGN shares. Goldman Sachs Group upped their price target on Regeneron Pharmaceuticals from $700.00 to $800.00 in a research report on Wednesday, August 5th. Oppenheimer upped their price target on Regeneron Pharmaceuticals from $675.00 to $725.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Cowen reaffirmed a “hold” rating and set a $584.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, June 2nd. Wells Fargo & Company raised Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $559.00 to $734.00 in a research report on Tuesday, May 26th. Finally, Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $657.00 to $691.00 and gave the company a “buy” rating in a research report on Friday, June 12th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $584.46.

Shares of Regeneron Pharmaceuticals stock traded down $6.37 during trading on Wednesday, hitting $573.53. 17,850 shares of the stock traded hands, compared to its average volume of 1,152,541. The stock has a market cap of $61.70 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 1.43 and a beta of 0.50. Regeneron Pharmaceuticals Inc has a 52 week low of $271.37 and a 52 week high of $664.64. The firm’s fifty day moving average is $604.38 and its 200-day moving average is $567.13. The company has a quick ratio of 1.68, a current ratio of 2.12 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $5.59 by $1.57. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.74 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. Regeneron Pharmaceuticals’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business posted $6.02 EPS. On average, analysts forecast that Regeneron Pharmaceuticals Inc will post 28.16 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 400 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $612.57, for a total value of $245,028.00. Following the completion of the sale, the chief financial officer now owns 24,334 shares in the company, valued at approximately $14,906,278.38. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 2,559 shares of the stock in a transaction that occurred on Friday, June 19th. The stock was sold at an average price of $630.02, for a total value of $1,612,221.18. Following the completion of the sale, the director now owns 3,202 shares of the company’s stock, valued at approximately $2,017,324.04. The disclosure for this sale can be found here. Insiders have sold a total of 163,328 shares of company stock valued at $99,804,711 over the last 90 days. 11.28% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: What is the S&P/ASX 200 Index?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply